Retapamulin: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Retapamulin. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Diarrhea | 2.3% |
| Headache | 2% |
| Nausea | 1.9% |
| Application site pruritus | 1.9% |
| Irritation | 1.6% |
| Pruritus | 1.6% |
| Pyrexia | 1.6% |
| Nasopharyngitis | 1.2% |
| Increased | 1% |
| Eczema | 1% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
ALTABAX is indicated for use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm2 in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes [see Clinical Studies (14)] . To reduce the development of drug-resistant bacteria and maintain the effectiveness of ALTABAX and other antibacterial drugs, ALTABAX should
Medical disclaimer: Always consult a qualified healthcare professional about any medication.